A Randomised Comparative Trial of Infusional ECF (Epirubicin, Cisplatin and 5-fluorouracil) versus Conventional AC (Adriamycin, Cyclophosphamide) as Primary (Neoadjuvant) Chemotherapy for Patients with at Least 3cm Diameter Early Breast Cancer

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

ISRCTN

Registry ID

ISRCTN19831176

Enrollment

426

Registered

2002-08-19

Start date

1993-10-01

Completion date

Unknown

Last updated

2015-01-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast cancer Cancer Breast

Interventions

1. Infusional ECF Regimen: Chemotherapy, ECF (epirubicin, cisplatin and 5-fluorouracil) treatment continuing 3 weekly for six courses 2. AC Regimen: Chemotherapy, AC (adriamycin, cyclophosphamide) tre

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: 1. Histologically or cytologically proven breast cancer 2. Aged <70 years 3. Potentially operable primary breast cancer more than 3 cm in diameter 4. Patients assessed as being competent to learn to look after Infumed or Graseby pump 5. World Health Organisation (WHO) performance status 0-1 6. No evidence of metastatic disease 7. Adequate haematological function 8. Glomerular filtration rate of at least 60 ml/min 9. No other serious uncontrolled medical condition 10. No other malignancy, except carcinoma in situ of the cervix or basal cell carcinoma of the skin

Exclusion criteria

Exclusion criteria: Not provided at time of registration

Design outcomes

Primary

Measure	Time frame
Not provided at time of registration	—

Secondary

Measure	Time frame
Not provided at time of registration	—

Countries

United Kingdom

Outcome results

None listed

Source: ISRCTN (via WHO ICTRP) · Data processed: Feb 4, 2026